Evidence map›Paper›PMID 37982733›Full record

ArticleACS nano2023

Viral Attachment Blocking Chimera Composed of DNA Origami and Nanobody Inhibits Pseudorabies Virus Infection In Vitro.

Swechchha Pradhan, Carter J Swanson, Chloe Leff, Isadonna Tengganu, Melissa H Bergeman, Gde B M Wisna, Ian B Hogue, Rizal F Hariadi

Open access · greenAbstract read
In one paragraph

Article in ACS nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Protective Effect of Nanobodies Targeting Sip Protein AgainstAnimals : an open access journal from MDPI · 2025
    Article
  3. Article
  4. In Vivo Interactions of Nucleic Acid Nanostructures With Cells.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Swechchha PradhanSchool for Engineering of Matter, Transport and Energy, Arizona State University, Tempe, Arizona 85281, United States.
Carter J SwansonBiodesign Center for Molecular Design and Biomimetics, Arizona State University, Tempe, Arizona 85281, United States.ORCID 0000-0001-6697-9475
Chloe LeffBiodesign Center for Molecular Design and Biomimetics, Arizona State University, Tempe, Arizona 85281, United States.
Isadonna TengganuBiodesign Center for Molecular Design and Biomimetics, Arizona State University, Tempe, Arizona 85281, United States.
Melissa H BergemanSchool of Life Science, Arizona State University, Tempe, Arizona 85281, United States.ORCID 0000-0001-8933-0599
Gde B M WisnaBiodesign Center for Molecular Design and Biomimetics, Arizona State University, Tempe, Arizona 85281, United States.
Ian B HogueSchool of Life Science, Arizona State University, Tempe, Arizona 85281, United States.
Rizal F HariadiBiodesign Center for Molecular Design and Biomimetics, Arizona State University, Tempe, Arizona 85281, United States.ORCID 0000-0001-7840-859X
Arizona State University · US

Funding

Nanoscale reconstruction of mechanical systems involved in disease pathogenesisDP2AI144247 · NIAID · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI HARIADI, RIZAL FAJAR · 2018 to 2018
$2.4M
NIAID NIH HHS DP2 AI144247
6 · The paper itself

Abstract

Antivirals are indispensable tools that can be targeted at viral domains directly or at cellular domains indirectly to obstruct viral infections and reduce pathogenicity. Despite their transformative use in healthcare, antivirals have been clinically approved to treat only 10 of the more than 200 known pathogenic human viruses. Additionally, many virus functions are intimately coupled with host cellular processes, which presents challenges in antiviral development due to the limited number of clear targets per virus, necessitating extensive insight into these molecular processes. Compounding this challenge, many viral pathogens have evolved to evade effective antivirals. We hypothesize that a viral attachment blocking chimera (VirABloC) composed of a viral binder and a bulky scaffold that sterically blocks interactions between a viral particle and a host cell may be suitable for the development of antivirals that are agnostic to the extravirion epitope that is being bound. We test this hypothesis by modifying a nanobody that specifically recognizes a nonessential epitope presented on the extravirion surface of pseudorabies virus strain 486 with a 3-dimensional wireframe DNA origami structure ∼100 nm in diameter. The nanobody switches from having no inhibitory properties to 4.2 ± 0.9 nM IC

Indexed as

Herpesvirus 1, SuidVirusesAnimalsAntiviral AgentsDNAEpitopesHumansVirus AttachmentAntiviral AgentsDNAEpitopesDNA nanotechnologyMultivalent inhibitorPRVSteric blockingViral inhibitor

Identifiers

PMID37982733
PMCPMC10787579
OpenAlexW4388825089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.